Communiqués COMPASS Pathways plc

Actions

CMPS

US20451W1018

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 17:52:58 29/07/2026			Varia. 5j.	Varia. 1 janv.
10,84 ^USD	-0,14%		-9,56%	+56,38%

27/07	COMPASS PATHWAYS PLC : Wells Fargo Securities dégrade son opinion à neutre	ZM
17/07	Les actions européennes cotées aux États-Unis sous forme d'ADR en repli ce vendredi	MT

Communiqués

12:31	Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026	BU
21/07	A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening	AQ
16/07	Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy	BU
07/07	Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile	BU
02/07	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
26/06	A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year	AQ
08/06	Compass Pathways Announces New Employee Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
05/06	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
02/06	FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate	AQ
28/05	COMPASS Pathways : 2026 AGM Voting Results	PU
28/05	Compass Pathways Elects Kathleen Tregoning to Board of Directors	BU
26/05	Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026	BU
14/05	Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026	BU
13/05	COMPASS Pathways : Leading the Transformation of Mental Health Care	PU
13/05	Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights	BU
06/05	Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026	BU
06/05	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
27/04	Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher	AQ
24/04	Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher	BU
21/04	Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments	BU
20/04	Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026	BU
18/04	Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments	BU
16/04	COMPASS Pathways : Ordinary Shareholder Proxy Form 2026 AGM	PU
16/04	Compass Pathways : Notice of 2026 AGM	PU
16/04	Compass Pathways : 2026 Proxy Statement	PU